Weleda AG   Report issue

For profit Phase 2 Phase 3
Founded: Arlesheim Switzerland (1921)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2006
NCT00552604
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

bryophyllum (1 trial)

cannabis (1 trial)

Drugs in Phase 2 Trials (1)

mistletoe extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Multiple Sclerosis (Phase 3)

Muscle Spasticity (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3